This study was designed to evaluate and compare safety, tolerability of subjects who
successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir.
This is a 48-week study, where subjects who were assigned to be in their original PI-group
have the option of switching to fosamprenavir on week 24. Prior to being assigned their
treatment group, subjects had to be suppressed for at least three months. All subjects also
take a background regimen of two nucleoside/nucleotide reverse transcriptase inhibitors.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
Fosamprenavir HIV Protease Inhibitors Protease Inhibitors